Impact of body mass index on outcomes of laparoscopic radical prostatectomy with long-term follow-up

Scandinavian Journal of Urology

Volumn 49, Issue 1, 2015, Pages 70-76

  Gözen, Ali Serdar ^a   Akin, Yigit ^a   Özden, Ender ^b   Ates, Mutlu ^c   Hruza, Marcel ^a   Rassweiler, Jens ^a  

^a SLK Kliniken Heilbronn   (Germany)

^b ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c Pediatric Bone Marrow Transplantation Unit   (Turkey)

Author keywords

Body mass index; Laparoscopy; Outcomes; Radical prostatectomy; Surgery

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER FUNCTION; BODY MASS; BODY WEIGHT; CANCER PATIENT; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEMOGRAPHY; FOLLOW UP; GLEASON SCORE; HEALTH IMPACT ASSESSMENT; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE PERIOD; LAPAROSCOPIC RADICAL PROSTATECTOMY; LAPAROSCOPIC SURGERY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; OPERATION DURATION; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; SURGICAL PATIENT; SURVIVAL RATE; TREATMENT OUTCOME; URINARY CONTINENCE; COMPLICATION; DISEASE FREE SURVIVAL; LAPAROSCOPY; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; TUMOR VOLUME;

AGED; BLOOD LOSS, SURGICAL; BODY MASS INDEX; DISEASE-FREE SURVIVAL; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OBESITY; OPERATIVE TIME; OVERWEIGHT; POSTOPERATIVE COMPLICATIONS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84920487021     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2014.920416     Document Type: Article

References (38)

1. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675-84.
2. Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 2005;93:1062-7.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348: 1625-38.
4. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
5. Moller E, Adami HO, Lundholm C, Bellocco R, Johansson JE, Gronberg H, et al. Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes Control 2013;24:2143-55.
6. Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis 2001;4:101-5.
7. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001;58:723-8.
8. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2001;22: 439-45.
9. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446-53.
10. Akin Y, Koksoy S, Yucel S, Erdogru T, Baykara M. Increased peripheral CD4+CD25 high Treg in prostate cancer patients is correlated with PSA. Saudi Med J 2011; 32:1003-8.
11. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent - update 2013. Eur Urol 2014;65:124-37.
12. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
13. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-43.
14. Rassweiler J, Marrero R, Hammady A. Transperitoneal laparoscopic radical prostatectomy: ascending technique. J Endourol 2004;18:593-9.
15. Rassweiler J, Wagner AA, Moazin M, Gözen AS, Teber D, Frede T, et al. Anatomic nerve-sparing laparoscopic radical prostatectomy: comparison of retrograde and antegrade techniques. Urology 2006;68:587-91.
16. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, et al. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011;24:16-25.
17. Hruza M, Weiss HO, Pini G, Goezen AS, Schulze M, Teber D, et al. Complications in 2200 consecutive laparoscopic radical prostatectomies: standardised evaluation and analysis of learning curves. Eur Urol 2010;58:733-41.
18. Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, et al. Nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007;25:3576-81.
19. Groves T. Pandemic obesity in Europe. BMJ 2006;333:1081.
20. Lopez-Jimenez F, Cortes-Bergoderi M. Update: Systemic diseases and the cardiovascular system (i): obesity and the heart. Rev Esp Cardiol 2011;64:140-9.
21. Magheli A, Rais-Bahrami S, Trock BJ, Humpheyres EB, Partin AW, Han M, et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 2008;72:1246-51.
22. Singh A, Fagin R, Shah G, Shekarriz B. Impact of prostate size and body mass index on perioperative morbidity after laparoscopic radical prostatectomy. J Urol 2005;173:552-4.
23. Brown JA, Rodin DM, Lee B, Dahl DM. Laparoscopic radical prostatectomy and body mass index: an assessment of 151 sequential cases. J Urol 2005;173:442-5.
24. Eden CG, Chang CM, Gianduzzo T, Moon DA. The impact of obesity on laparoscopic radical prostatectomy. BJU Int 2006;98:1279-82.
25. Morote J, Celma A, Planas J, Placer J, Konstantinidis C, Iztueta I, et al. Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressiveness. Actas Urol Esp 2014;38:232-7.
26. De Pergola Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013;2013:291546.
27. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007;109:1192-202.
28. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-9.
29. Parker AS, Thiel DD, Bergstralh E, Carlson RE, Rangel LJ, Joseph RW, et al. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis 2013;16:352-6.
30. Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, et al. Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology 2012; 80:576-84.
31. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1998;73:401-6.
32. Kok DE, van Roermund JG, Aben KK, van de Luijtgaarden MW, Karthaus HF, van Vierssen Trip OB, et al. Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer. World J Urol 2011;29:695-701.
33. van Roermund JG, Kok DE, Wildhagen MF, Kiemeney LA, Struik F, Sloot S, et al. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU Int 2009;104:321-5.
34. Wiltz AL, Shikanov S, Eggener SE, Katz MH, Thong AE, Steinberg GD, et al. Robotic radical prostatectomy in overweight and obese patients: oncological and validatedfunctional outcomes. Urology 2009;73:316-22.
35. Rassweiler J, Stolzenburg J, Sulser T, Deger S, Zumbe J, Hofmockel G, et al. Laparoscopic radical prostatectomy - the experience of the German Laparoscopic Working Group. Eur Urol 2006;49:113-19.
36. Sundi D, Reese AC, Mettee LZ, Trock BJ, Pavlovich CP. Laparoscopic and robotic radical prostatectomy outcomes in obese and extremely obese men. Urology 2013;82: 600-5.
37. Ahlering TE, Eichel L, Edwards R, Skarecky DW. Impact of obesity on clinical outcomes in robotic prostatectomy. Urology 2005;65:740-4.
38. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011;4: 486-501.